Culbertson A N & Co. Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,908 shares of the company’s stock after selling 312 shares during the period. Johnson & Johnson comprises 3.1% of Culbertson A N & Co. Inc.’s portfolio, making the stock its 5th largest position. Culbertson A N & Co. Inc.’s holdings in Johnson & Johnson were worth $9,645,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in JNJ. Bluestein R H & Co. increased its stake in Johnson & Johnson by 58.2% in the fourth quarter. Bluestein R H & Co. now owns 33,906 shares of the company’s stock valued at $3,906,000 after buying an additional 12,467 shares in the last quarter. Smith Shellnut Wilson LLC ADV purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $4,837,000. Meridian Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $470,000. Lyell Wealth Management LP bought a new position in Johnson & Johnson during the fourth quarter worth about $751,000. Finally, Shelton Capital Management increased its position in Johnson & Johnson by 18.3% in the fourth quarter. Shelton Capital Management now owns 73,221 shares of the company’s stock worth $8,436,000 after buying an additional 11,307 shares during the last quarter. 66.10% of the stock is currently owned by institutional investors.
Johnson & Johnson (NYSE JNJ) opened at 132.63 on Friday. The stock has a market cap of $355.98 billion, a price-to-earnings ratio of 22.44 and a beta of 0.78. The firm’s 50-day moving average price is $132.88 and its 200 day moving average price is $127.04. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter in the previous year, the firm posted $1.74 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/19/culbertson-a-n-co-inc-has-9-65-million-position-in-johnson-johnson-nysejnj-updated.html.
A number of research analysts recently issued reports on JNJ shares. UBS AG reiterated a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. Cowen and Company reiterated a “buy” rating and issued a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price for the company in a research note on Thursday, May 18th. BMO Capital Markets reiterated a “buy” rating and issued a $132.00 target price on shares of Johnson & Johnson in a research note on Friday, June 2nd. Finally, Royal Bank Of Canada restated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 15th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $134.12.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
